257 related articles for article (PubMed ID: 30653423)
1. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
Hayashi H; Kurata T; Takiguchi Y; Arai M; Takeda K; Akiyoshi K; Matsumoto K; Onoe T; Mukai H; Matsubara N; Minami H; Toyoda M; Onozawa Y; Ono A; Fujita Y; Sakai K; Koh Y; Takeuchi A; Ohashi Y; Nishio K; Nakagawa K
J Clin Oncol; 2019 Mar; 37(7):570-579. PubMed ID: 30653423
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).
Yoon HH; Foster NR; Meyers JP; Steen PD; Visscher DW; Pillai R; Prow DM; Reynolds CM; Marchello BT; Mowat RB; Mattar BI; Erlichman C; Goetz MP
Ann Oncol; 2016 Feb; 27(2):339-44. PubMed ID: 26578722
[TBL] [Abstract][Full Text] [Related]
3. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
[TBL] [Abstract][Full Text] [Related]
4. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
Hainsworth JD; Daugaard G; Lesimple T; Hübner G; Greco FA; Stahl MJ; Büschenfelde CM; Allouache D; Penel N; Knoblauch P; Fizazi KS
Cancer; 2015 May; 121(10):1654-61. PubMed ID: 25611313
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Hainsworth JD; Spigel DR; Thompson DS; Murphy PB; Lane CM; Waterhouse DM; Naot Y; Greco FA
Oncologist; 2009 Dec; 14(12):1189-97. PubMed ID: 19965914
[TBL] [Abstract][Full Text] [Related]
7. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
[TBL] [Abstract][Full Text] [Related]
8. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
Rassy E; Pavlidis N
Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.
Hainsworth JD; Schnabel CA; Erlander MG; Haines DW; Greco FA
Clin Colorectal Cancer; 2012 Jun; 11(2):112-8. PubMed ID: 22000811
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
Langer CJ; O'Byrne KJ; Socinski MA; Mikhailov SM; Leśniewski-Kmak K; Smakal M; Ciuleanu TE; Orlov SV; Dediu M; Heigener D; Eisenfeld AJ; Sandalic L; Oldham FB; Singer JW; Ross HJ
J Thorac Oncol; 2008 Jun; 3(6):623-30. PubMed ID: 18520802
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
[TBL] [Abstract][Full Text] [Related]
12. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
Lhommé C; Joly F; Walker JL; Lissoni AA; Nicoletto MO; Manikhas GM; Baekelandt MM; Gordon AN; Fracasso PM; Mietlowski WL; Jones GJ; Dugan MH
J Clin Oncol; 2008 Jun; 26(16):2674-82. PubMed ID: 18509179
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Sep; 14(9):828-32. PubMed ID: 17760750
[TBL] [Abstract][Full Text] [Related]
14. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
[TBL] [Abstract][Full Text] [Related]
15. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
16. Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer.
Brooks GA; Austin AM; Uno H; Dragnev KH; Tosteson ANA; Schrag D
JAMA Netw Open; 2018 Oct; 1(6):e183023. PubMed ID: 30646220
[TBL] [Abstract][Full Text] [Related]
17. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
[TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.
Briasoulis E; Kalofonos H; Bafaloukos D; Samantas E; Fountzilas G; Xiros N; Skarlos D; Christodoulou C; Kosmidis P; Pavlidis N
J Clin Oncol; 2000 Sep; 18(17):3101-7. PubMed ID: 10963638
[TBL] [Abstract][Full Text] [Related]
20. [Genomic Analysis-Based Treatment for Cancer of Unknown Primary].
Nishio K
Gan To Kagaku Ryoho; 2022 Mar; 49(3):259-263. PubMed ID: 35299177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
